NASDAQ:XTLB XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free XTLB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.45▼$2.5850-Day Range$3.43▼$5.2052-Week Range$1.73▼$6.69Volume33,017 shsAverage Volume136,363 shsMarket Capitalization$13.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsEarningsHeadlinesShort InterestSocial MediaStock AnalysisCompetitorsEarningsHeadlinesShort InterestSocial Media Get XTL Biopharmaceuticals alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About XTL BiopharmaceuticalsXTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.Read More Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. XTLB Stock News HeadlinesMarch 20, 2024 | msn.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%March 20, 2024 | msn.comUS Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top ViewsApril 25, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...March 20, 2024 | markets.businessinsider.comDow Surges 350 Points; Fed Holds Rates SteadyMarch 20, 2024 | markets.businessinsider.comCrude Oil Surges 2%; Signet Jewelers Shares Spike HigherMarch 20, 2024 | globenewswire.comXTL To Aquire The Social ProxyFebruary 17, 2024 | investing.comXTL Biopharmaceuticals Ltd ADR (XTLB)October 23, 2023 | finance.yahoo.comXTL Biopharmaceuticals Ltd (H2K2.MU)April 25, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...October 23, 2023 | finanznachrichten.deXTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyOctober 21, 2023 | finanznachrichten.deXTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelOctober 20, 2023 | finance.yahoo.comXTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelOctober 20, 2023 | finance.yahoo.comXTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyOctober 1, 2022 | seekingalpha.comXTLB XTL Biopharmaceuticals Ltd.August 8, 2022 | reuters.comX T L Biopharmaceuticals LtdJuly 23, 2022 | seekingalpha.comLIFE, TBLT and XTLB among pre market gainersDecember 15, 2021 | uk.finance.yahoo.comXTL Biopharmaceuticals Ltd. (XTLB)See More Headlines Receive XTLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XTLB CUSIPN/A CIK1023549 Webwww.xtlbio.com Phone(729) 955-7080Fax972-3611-6605EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.05% Return on Assets-68.83% Debt Debt-to-Equity RatioN/A Current Ratio14.09 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book3.51Miscellaneous Outstanding Shares5,450,000Free Float3,869,000Market Cap$13.95 million OptionableNot Optionable Beta1.21 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesShlomo Spokone ShalevChief Executive Officer & Executive DirectorItay WeinsteinChief Financial OfficerDaphna ParanMedical DirectorKey CompetitorsTraws PharmaNASDAQ:TRAWABVC BioPharmaNASDAQ:ABVCEdesa BiotechNASDAQ:EDSANanoViricidesNYSE:NNVCNeuroBo PharmaceuticalsNASDAQ:NRBOView All Competitors XTLB Stock Analysis - Frequently Asked Questions Are investors shorting XTL Biopharmaceuticals? XTL Biopharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 437,200 shares, an increase of 21,760.0% from the March 15th total of 2,000 shares. Based on an average daily volume of 720,600 shares, the short-interest ratio is currently 0.6 days. View XTL Biopharmaceuticals' Short Interest. When is XTL Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our XTLB earnings forecast. When did XTL Biopharmaceuticals' stock split? XTL Biopharmaceuticals's stock reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of XTL Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other XTL Biopharmaceuticals investors own include Sorrento Therapeutics (SRNE), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Akari Therapeutics (AKTX), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Gilead Sciences (GILD), Novus Therapeutics (NVUS) and Regulus Therapeutics (RGLS). This page (NASDAQ:XTLB) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
